Compare XEL & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XEL | ONC |
|---|---|---|
| Founded | 1909 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2B | 33.5B |
| IPO Year | 2003 | N/A |
| Metric | XEL | ONC |
|---|---|---|
| Price | $81.40 | $299.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | $84.36 | ★ $386.70 |
| AVG Volume (30 Days) | ★ 4.2M | 224.8K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.42 | N/A |
| Revenue | ★ $11,537,000,000.00 | N/A |
| Revenue This Year | $9.67 | $759.19 |
| Revenue Next Year | $8.02 | $14.51 |
| P/E Ratio | ★ $23.97 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $65.21 | $196.53 |
| 52 Week High | $84.23 | $385.22 |
| Indicator | XEL | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 54.49 | 34.99 |
| Support Level | $71.95 | $292.79 |
| Resistance Level | $82.51 | $300.00 |
| Average True Range (ATR) | 1.33 | 9.26 |
| MACD | -0.35 | -4.29 |
| Stochastic Oscillator | 26.58 | 12.16 |
Xcel Energy manages utilities serving 3.9 million electric customers and 2.2 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy suppliers in the US, with more than half of its electricity sales coming from carbon-free energy.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.